Canadian Cannabis Companies Eye U.S. Opportunities After Rescheduling Shift

Canadian cannabis companies are beginning to clarify how they plan to engage with the U.S. market following President Donald Trump’s December 18 executive order directing federal agencies to reclassify cannabis from Schedule I to Schedule III.

The move does not legalize cannabis at the federal level, but it does reshape the regulatory backdrop in ways that matter for medical cannabis, research, CBD and certain federally compliant commercial pathways. For Canadian operators long sidelined from direct U.S. THC exposure, the order is being treated less as a green light and more as a normalization signal, one that could gradually expand addressable markets without eliminating execution risk.

Tilray Builds a Medical-First U.S. Strategy

Tilray Brands was among the fastest to outline a concrete response. The company launched Tilray Medical USA, signaling a renewed push into federally compliant medical cannabis channels tied to research, regulated supply and pharmaceutical-style standards.

Rather than framing rescheduling as an adult-use opportunity, Tilray’s messaging emphasizes medical legitimacy and institutional readiness, a posture aligned with how Schedule III substances are typically regulated in the U.S.

Canopy Growth’s U.S. Exposure Runs Through Canopy USA

Canopy Growth publicly welcomed the rescheduling order as a step toward modernizing U.S. cannabis policy. But the company’s positioning is best understood through Canopy USA, the U.S.-focused holding structure it has spent years assembling.

Through Canopy USA, the company already controls or holds interests in several major U.S. cannabis assets, including Wana Brands (edibles), Jetty (extracts) and Acreage Holdings, a multi-state operator with retail and cultivation exposure. That structure allows Canopy to participate in U.S. cannabis upside if federal constraints loosen further, without assuming that adult-use legalization is imminent.

In that context, Canopy’s response to rescheduling reflects preparedness rather than urgency; an acknowledgment that policy momentum is moving in a direction the company has long anticipated.

Avicanna Leans Into Science and Drug-Development Pathways

Avicanna took a different approach, explicitly framing the executive order through a scientific and pharmaceutical lens. In a public statement, the company applauded the reclassification directive while highlighting how Schedule III status could expand research opportunities and accelerate evidence-based cannabinoid medicine development in the U.S.

Avicanna paired its policy response with a scientific update, underscoring its strategy of aligning cannabinoid products with clinical data, regulatory standards and potential FDA-adjacent pathways, rather than consumer retail expansion.

High Tide and Village Farms See Opportunity in CBD and Wellness

Other Canadian companies are focusing on federally compliant wellness channels, particularly CBD.

High Tide welcomed the executive order as one of the most significant cannabis policy shifts in decades, pointing to opportunities in CBD products, Medicare-aligned wellness categories and potential U.S. licensing pathways for its retail and brand portfolio.

Village Farms International, which owns the U.S.-based CBDistillery brand, also praised the move and said it could support expansion of its U.S. operations, particularly in hemp-derived and medical cannabis products positioned within existing federal frameworks.

A Signal, Not a Switch

Across the board, Canadian operators are sending a similar message: rescheduling changes the conversation, not the commercial reality overnight.

Most companies are emphasizing:

• Medical cannabis and research
• CBD and wellness products
• Brand licensing and structured U.S. exposure
• Regulatory preparedness rather than rapid expansion

Key barriers, including interstate commerce restrictions, adult-use federal illegality and unresolved banking issues, remain firmly in place. For investors, the takeaway is that rescheduling may gradually improve cash flow dynamics, research access and institutional comfort, but it does not eliminate regulatory risk.

For Canadian cannabis companies, the U.S. market is no longer a distant hypothetical. But it is still a market that must be entered carefully, through lanes that align with federal law as it exists, not as the industry hopes it will be.

Photo by Walter Martin on Unsplash